Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[This has led to the question of whether EGFR remains a viable target in patients other than those whose tumors contain mutations, and whether the modest activity of cetuximab in colorectal cancer and head and neck cancer represents all that we can expect from inhibition of this pathway in the absence of mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[This has led to the question of whether EGFR remains a viable target in patients other than those whose tumors contain mutations, and whether the modest activity of cetuximab in colorectal cancer and head and neck cancer represents all that we can expect from inhibition of this pathway in the absence of mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This has led to the question of whether EGFR remains a viable target in patients other than those whose tumors contain mutations, and whether the modest activity of cetuximab in colorectal cancer and head and neck cancer represents all that we can expect from inhibition of this pathway in the absence of mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This has led to the question of whether EGFR remains a viable target in patients other than those whose tumors contain mutations, and whether the modest activity of cetuximab in colorectal cancer and head and neck cancer represents all that we can expect from inhibition of this pathway in the absence of mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_assertion description "[This has led to the question of whether EGFR remains a viable target in patients other than those whose tumors contain mutations, and whether the modest activity of cetuximab in colorectal cancer and head and neck cancer represents all that we can expect from inhibition of this pathway in the absence of mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586069.RAdd_gbXm9Et9VP72woZAt7Q7TrGPmrYhXjTwfNcOhAO8130_provenance.
• NP586070.RAjVl-vP-A4UZ3oKnpAMCW9bqBZbCIAa75Dktw_Nvr39o130_assertion description "[This has led to the question of whether EGFR remains a viable target in patients other than those whose tumors contain mutations, and whether the modest activity of cetuximab in colorectal cancer and head and neck cancer represents all that we can expect from inhibition of this pathway in the absence of mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586070.RAjVl-vP-A4UZ3oKnpAMCW9bqBZbCIAa75Dktw_Nvr39o130_provenance.
• NP586068.RAyoFuSERCbSMuQ4gECUhRKkH3xAW8i3PeIxlzuNBjjA8130_assertion description "[This has led to the question of whether EGFR remains a viable target in patients other than those whose tumors contain mutations, and whether the modest activity of cetuximab in colorectal cancer and head and neck cancer represents all that we can expect from inhibition of this pathway in the absence of mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586068.RAyoFuSERCbSMuQ4gECUhRKkH3xAW8i3PeIxlzuNBjjA8130_provenance.